ISIS PHARMACEUTICALS $20.98

up +0.34


24/5/2013 04:24 PM  |  NASDAQ : ISIS  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 121% - ISIS has outperformed the S&P 500 by 96%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. $176,000 or $295,00 a Year: Bizarre World of Orphan Drugs

    YCharts

  2. Market Wrap for Wednesday, January 30: Stocks Fall as Economy ...

    Benzinga

  3. Mid-Day Market Update: BlackBerry 10 Release Sends Shares Lower, ...

    Benzinga

  4. UPDATE: Jefferies Reiterates Underperform Rating, Raises PT on ...

    Benzinga

  5. Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, ...

    Benzinga

  6. Isis Pharmaceuticals (ISIS) Chairman, CEO and President Stanley T ...

    GuruFocus

  7. UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises ...

    Benzinga

  8. Mid-Afternoon Market Update: Markets Fall Further, Isis Pharma Rallies

    Benzinga

  9. Foreign Drugmakers Holding Up, But Some Have Flaws

    Investors Business Daily

  10. Benzinga's Top Pre-Market Losers

    Benzinga

  11. Isis Pharma Announces Fast Track Designation for ISIS-TTR Rx for ...

    Benzinga

  12. Piper Jaffray Reiterates Neutral Rating, $10 PT on ISIS ...

    Benzinga

  13. Biogen, Isis Pharma Announce Collaboration for Antisense Programs

    Benzinga

  14. Isis Pharma Posts Positive Phase 1 Data on Three Drugs in ...

    Benzinga

  15. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga

  16. Mid-Afternoon Market Update: Markets Slow Their Rally; Groupon ...

    Benzinga

  17. Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses ...

    Benzinga

  18. Isis Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus

  19. BioMarin Stock Soars On Positive Drug Data

    Investors Business Daily

  20. Isis Pharmaceuticals To Receive $1.1 Million From Alnylam

    Benzinga

  21. Benzinga Mid-Morning Market Update

    Benzinga

  22. FDA Advisory Committee Votes to Recommend Isis' KYNAMRO

    Benzinga

  23. Benzinga Mid-Afternoon Market Update

    Benzinga

  24. ISIS Pharmaceuticals Trader Expects an Extended Decline

    By SchaeffersResearch

  25. Benzinga Mid-Day Market Update

    Benzinga

  26. Benzinga Mid-Morning Market Update

    Benzinga

  27. Benzinga Mid-Afternoon Market Update

    Benzinga

  28. Benzinga Mid-Day Market Update

    Benzinga

  29. Isis Pharmaceuticals

    Investors Business Daily

  30. Benzinga Mid-Afternoon Market Update

    Benzinga

  31. UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral ...

    Benzinga

  32. Benzinga Mid-Morning Market Update

    Benzinga

  33. Morning Market Losers

    Benzinga

  34. Benzinga's Top Pre-Market Losers

    Benzinga

  35. Isis Pharmaceuticals Inc. (ISIS) Chairman, CEO and President ...

    GuruFocus

  36. ISIS Pharmaceuticals, Inc. (ISIS) Chairman, CEO and President ...

    GuruFocus

  37. ISIS Pharmaceuticals, Inc. (ISIS) COO, Secretary B Lynne Parshall ...

    GuruFocus

  38. Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry ...

    Benzinga

  39. Isis Pharma to Receive $1.4M from Alnylan

    Benzinga

  40. Regulus Files Registration Statement for Proposed Initial Public ...

    Benzinga

  41. Isis Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus

  42. Isis Pharmaceuticals Announces Proposed Offering of $175 Million ...

    Benzinga

  43. Equity Moves on Sell-Side Sentiment for July 19, 2012

    Benzinga

  44. UPDATE: Jefferies Downgrades ISIS Pharmaceuticals from Buy to ...

    Benzinga

  45. UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on ...

    Benzinga

  46. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FOXBusiness

  47. US Airways Group, General Growth Properties Among Stocks Hitting ...

    FOXBusiness

  48. Puts Gain Popularity as Isis Pharmaceuticals Explores New Highs

    By SchaeffersResearch

  49. Merck &, Onyx Pharmaceuticals Among Stocks Hitting 52-Week Highs ...

    FOXBusiness

  50. DSW, Pharmacyclics, Other Stocks Hit 52-Week Highs Tuesday

    FOXBusiness

  51. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with ...

    Benzinga

  52. Piper Jaffray: ISIS Pharmaceuticals Initiates Phase I Study

    at Benzinga

  53. Biogen joins Isis on spinal drug

    at IBD

  54. Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall ...

    at GuruFocus

  55. Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley ...

    at GuruFocus
People viewing ISIS also viewed: , , , , , ,
Marketplace
Trading Center